The Moriarity laboratory is studying the genetics of pediatric cancer, including sarcomas and brain tumors, to identify novel therapeutic targets to better treat pediatric cancer patients. The lab uses animal models and comparative genomics approaches to identify new candidate cancer genes. Once identified, candidate genes are functionally studied in human cancer and immortalized cell lines using cutting edge technologies, such as targeted nucleases. The primary targeted nucleases used in the lab are the CRISPR/Cas9 and Transcriptional Activator-Like Effector (TALEN) systems, which are used to knockout genes, induce targeted sequence changes, and activate and/or repress endogenous gene expression.
This group's research was featured on the MSI website in May 2019: A Tool to Identify Cancer Genes.